乳腺癌研究进展

       　乳腺癌是发生在乳房腺上皮组织的恶性肿瘤。是一种严重影响妇女身心健康甚至危及生命的最常见的恶性肿瘤之一。近年来，无论在基础研究、发病机理， 还是临床早期诊断和防治上都取得很大的进展。我们曾在202期做过乳腺癌的特别报道，近期CMBI又为大家搜集了在国际刊物上发表的乳腺癌研究进展的相关综述，供基础和临床参考， 更多的文献资料，请用相关关键词通过CMBI文献查询获取。

• Goals of Treatment for Patients With Metastatic Breast Cancer
  
• The prevention, detection, and management of breast cancer
  
• The intraductal approach to breast cancer biomarker discovery
  
• The impact of expression profiling on prognostic and predictive testing in breast cancer
  
• Role of Gemcitabine in Breast Cancer Management
  
• prediction and prevention of breast cancer—cellular and molecular interactions
  
• Multitargeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
  
• Male breast cancer
  
• Magnetic Resonance Imaging of the Breast
  
• Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer
  
• High-throughput techniques in breast cancer
  
• Herceptin-HERalding a new era in breast cancer care but at what cost
  
• Gene Expression Profiling of Breast Cancer
  
• Future Directions in Breast Imaging
  
• Conventional Radiation Therapy As Part of Breast-Conserving Treatment
  
• Clinical Experience With Pemetrexed in Breast Cancer
  
• Association of Ginseng Use with Survival and Quality of Life among Breast Cancer Patients
  
• Advances in Breast Conservation Therapy
  
• Adjuvant Endocrine Therapy for Premenopausal Women With Early
  
• The Use of Genetic SNPs as New Diagnostic Markers in Preventive Medicine
  
• Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer
  
• Tissue inhibitor of metalloproteinases-1 in breast cancer
  
• Sex steroid-producing enzymes in human breast cancer
  
• Related Lymphedema
  
• Partial-breast treatment for early breast cancer
  
• Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
  
• Mammary developmental fate and breast cancer risk
  
• Genomics in breast cancer—therapeutic implications
  
• Controversies in the Therapy of Early Stage Breast Cancer
  
• Breast-tissue sampling for risk assessment and prevention
  
• Adjuvant Chemotherapy for Early Breast Cancer
  
• vaccines
  
• risk with postmenopausal hormonal treatment
  
• Performance and Reporting of Clinical Breast Examination
  
• Clinical Breast Examination
  
• Adjuvant chemotherapy in elderly patients with breast cancer
  
• p53 signatures in breast cancer
  
• Long-term risk of breast cancer recurrence
  
• Fine-Tuning Breast Density Measures
  
• Evolving Understanding of Growth Regulation in Human Breast Cancer
  
• International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
  
• Dissecting a Hidden Breast Cancer Risk
  
• Cyclin D1 in Breast Cancer Pathogenesis
  
• Telomerase in Breast Cancer
  
• Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered
  
• Bisphosphonates in breast cancer
  
• Gene expression profiling of breast cancer_a new tumor marker
  
• Tumor cell invasion and survival in head and neck cancer
  
• The role of B-RAF in melanoma
  
• Progression of head and neck squamous cell cancer
  
• Molecular therapy of head and neck cancer
  
• Molecular markers for diagnosis and prognosis
  
• Immunobiology of head and neck cancer
  
• Human papillomavirus in head and neck cancer-Molecular biology and clinicopathological correlations
  
• Gene therapy for head and neck cancer
  
• Gene profiling in squamous cell carcinoma of the head and neck
  
• Estimating the number of rate limiting genomic changes for human breast cancer
  
• Epidemiology of head and neck cancer-Magnitude of the problem
  
• Characterization of a human breast cancer cell line-MCF-7-RU58R-1-resistant to the pure antiestrogen RU 58-668
  
• Biological significance of c-erbB family oncogenes in head and neck cancer
  
• Towards discovery-driven translational research in breast cancer
  
• Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older
  
• Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen
  
• Landmark trials in endocrine adjuvant therapy for breast carcinoma
  
• Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
  
• Aromatase inhibitors as adjuvant treatment of breast cancer
  
• Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
  
• What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile
  
• Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
  
• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
  
• Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer
  
• Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer
  
• Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy
  
• -Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer
  
• Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer